This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Relapse Prevention Study in Patients With Schizoph...
Clinical trial

Relapse Prevention Study in Patients With Schizophrenia (REPRIEVE)

Read time: 1 mins
Last updated:1st Feb 2011

The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia


Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension
Enrollment: 303
Study Start Date: February 2011
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)

Arms:
- Experimental:
Iloperidone
- Placebo Comparator: Iloperidone (including Placebo)

Category Value
Study start date 2011-02-01

View full details